A Generalised Model for Valuing Early Stage Technology Palisade Europe User Conference 2008 Michael Brand © 2008 Captum Capital Limited.

Slides:



Advertisements
Similar presentations
Welcome to the Open Court Business Plan Executive Summary Template!
Advertisements

TWO STEP EQUATIONS 1. SOLVE FOR X 2. DO THE ADDITION STEP FIRST
You have been given a mission and a code. Use the code to complete the mission and you will save the world from obliteration…
Go-to-Market Strategy
McGraw-Hill/Irwin Copyright © 2012 by The McGraw-Hill Companies, Inc. All rights reserved.
Chapter 10 Learning Objectives
Chapter 13 Learning Objectives
Technology Commercialisation System Richard Linley Associate Consultant.
CTI LIFE SCIENCES FUND Role of a VC in Helping Commercialize Early Stage Innovation November 19 th 2007 Presented by: Richard J. Meadows Managing Partner.
1 PowerPointPresentation by PowerPoint Presentation by Gail B. Wright Professor Emeritus of Accounting Bryant University © Copyright 2007 Thomson South-Western,
Cost Management ACCOUNTING AND CONTROL
Chapter 19 Financing and Valuation Principles of Corporate Finance
1 Copyright © 2010, Elsevier Inc. All rights Reserved Fig 2.1 Chapter 2.
By D. Fisher Geometric Transformations. Reflection, Rotation, or Translation 1.
Advertising, Sales Promotion, and Public Relations
Business Transaction Management Software for Application Coordination 1 Business Processes and Coordination.
Jeopardy Q 1 Q 6 Q 11 Q 16 Q 21 Q 2 Q 7 Q 12 Q 17 Q 22 Q 3 Q 8 Q 13
Jeopardy Q 1 Q 6 Q 11 Q 16 Q 21 Q 2 Q 7 Q 12 Q 17 Q 22 Q 3 Q 8 Q 13
Title Subtitle.
0 - 0.
DIVIDING INTEGERS 1. IF THE SIGNS ARE THE SAME THE ANSWER IS POSITIVE 2. IF THE SIGNS ARE DIFFERENT THE ANSWER IS NEGATIVE.
MULTIPLYING MONOMIALS TIMES POLYNOMIALS (DISTRIBUTIVE PROPERTY)
ADDING INTEGERS 1. POS. + POS. = POS. 2. NEG. + NEG. = NEG. 3. POS. + NEG. OR NEG. + POS. SUBTRACT TAKE SIGN OF BIGGER ABSOLUTE VALUE.
SUBTRACTING INTEGERS 1. CHANGE THE SUBTRACTION SIGN TO ADDITION
MULT. INTEGERS 1. IF THE SIGNS ARE THE SAME THE ANSWER IS POSITIVE 2. IF THE SIGNS ARE DIFFERENT THE ANSWER IS NEGATIVE.
Addition Facts
NPV.
1 MN20211 Advanced Corporate Finance Revision Session.
IdMRC THEME Design Information & Knowledge Estimating and Managing Through Life Costs Presenter Linda Newnes
Welcome to Who Wants to be a Millionaire
Welcome to Who Wants to be a Millionaire
ZMQS ZMQS
ANALYZING AND ADJUSTING COMPARABLE SALES Chapter 9.
Richmond House, Liverpool (1) 26 th January 2004.
BT Wholesale October Creating your own telephone network WHOLESALE CALLS LINE ASSOCIATED.
What is business planning?What is the objective of a business plan? What are the main steps of a business plan? Business Planning (2)
ABC Technology Project
What is Mike’s Bikes? Single-player version (SoloMike)
Fifth Edition 1 M a n a g e m e n t I n f o r m a t i o n S y s t e m s M a n a g I n g I n f o r m a t i o n T e c h n o l o g y i n t h e E – B u s i.
Chapter 10 Project Cash Flows and Risk
© S Haughton more than 3?
CHAPTER 4 MEASURES OF LEVERAGE Presenter’s name Presenter’s title dd Month yyyy.
Global Entrepreneurship and Small Business Management
Squares and Square Root WALK. Solve each problem REVIEW:
Risk Management & Real Options IX. Flexibility in Contracts Stefan Scholtes Judge Institute of Management University of Cambridge MPhil Course
Chapter 5 Test Review Sections 5-1 through 5-4.
GG Consulting, LLC I-SUITE. Source: TEA SHARS Frequently asked questions 2.
Tools for Improving Competitiveness María De Los Ángeles Rivera, CPA – Partner, Kevane Grant Thornton Red de Mujeres Empresarias CCPR January 19, 2012.
Addition 1’s to 20.
25 seconds left…...
Slippery Slope
Test B, 100 Subtraction Facts
Week 1.
We will resume in: 25 Minutes.
A small truth to make life 100%
Marketing Strategy and the Marketing Plan
A SMALL TRUTH TO MAKE LIFE 100%
1 Unit 1 Kinematics Chapter 1 Day
1 PART 1 ILLUSTRATION OF DOCUMENTS  Brief introduction to the documents contained in the envelope  Detailed clarification of the documents content.
Supply Chain Performance Measurement
Copyright © 2009 The McGraw-Hill Companies, Inc., All Rights Reserved. McGraw-Hill/Irwin.
Supply Chain Performance Measurement
How Cells Obtain Energy from Food
One line description - easy to understand and remember
 Copyright 2008 by Axendia, Inc. 1 Prepared for Advamed 2008 What You Should Know About Launching Medical Devices in the North American Market By Daniel.
[This slide should be deleted before use]
Copyright © 2004 Pearson Education Canada Inc Personal Selling Today Introduction and Overview CHAPTER.
The Student Handbook to T HE A PPRAISAL OF R EAL E STATE 1 Chapter 23 Yield Capitalization — Theory and Basic Applications.
1 (of 26) IBUS 302: International Finance Topic 15-Currency Swaps Lawrence Schrenk, Instructor.
September 12, 2002CFO Roundtable - Valuing Biotech.
Presentation transcript:

A Generalised Model for Valuing Early Stage Technology Palisade Europe User Conference 2008 Michael Brand © 2008 Captum Capital Limited

2 About Captum… Formed in 2004 Transatlantic presence Specialised consulting to: –Private companies (pre-IPO ) –Life science sector (Biotech, Med Dev, Pharma) –Business development, valuation, partnering MasterClasses in Finance, Leadership –Valuation Masterclass attended by over 350 executives in UK and Europe

3 Valuing Technology Technical Risk –Will it work? –Scale up issues –Regulatory hurdles Market Risk –Customer acceptance –Pricing issues –Competition

4 Valuing Risk £ X £200,000 £0 0.5 or What value of X are you indifferent between a fixed sum and playing the game? £1 £1,000 £10,000 £20,000 £50,000 £100,000

5 Valuing Technology Early-stage Technology Company Development Cost NPV Success NPV Failure

6 Valuation Parameters Cash Flow Probability of achieving cash flow Discount rate (less uncertain) CsCs CfCf P (1 – P) t

7 Stepwise Development ConceptDevelopmentManufacturingMarket launch Development can fail at any milestone along the development pathway

8 Drug Discovery Process Pre- Clinical Phase 1Phase 2Phase 3FDA S F S S S S F F F F

9 General Value Model Risk Adjusted NPV = Risk Adjusted NPV Sales Income Risk Adjusted NPV Development Cost +

10 Case: ReJuven8 Innovative wound care treatment Demonstrated on animals, limited human trial Requires manufacturing scale-up for: –Small and Large scale human clinical trials –FDA Approval Post FDA approval, sales launch This case has been written by Captum Capital Limited for educational purposes only. Any resemblance to any actual person, company, organization or technology is entirely accidental. Data included in this case is for illustration only, and should not be relied on for accuracy.

11 ReJuven8 Development Scale upCT1CT2FDA Cash Flow $m Overall Probability of FDA Approval = 0.15

12 ReJuven8 PreSales Model

13 Binary Decisions

14 ReJuven8 Presales NPV

15 Forecasting Sales Top Down Bottom Up Total Market Size ($/yr) Market Share (%) Price/unit ($/unit) User Penetration (%) Potential Users (units) Sales

16 Market Penetration P t = K P o e kt K + P o (e kt – 1) P 0 =1 K=10 PtPt Time, t abc k a =2 b =1 c =0.5 Verhulst Pearl Equation

17 Adding Post Launch Sales

18 ReJuven8 Post Sales NPV

19 Year 1 Sales Distribution

20 ReJuven8 3 Year Sales

21 ReJuven8 5 Year Sales

22 Summary Model Advantages –Graphical depiction of technology/market risk –Flexible: facilitates development strategy –Intuitive: based on realistic probabilities –Effective communication tool Downside –Valuing very early stage technology difficult –Most investors are risk adverse (<eNPV) –Requires analytical discipline

23 Contact Michael Brand e: t: +44 (0) m: +44 (0) Captum Capital Limited Cumberland House 35 Park Row Nottingham NG1 6EE United Kingdom